NYSE:GKOSMedical Equipment
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For Keratoconus - What's Changed
In March 2026, Glaukos Corporation announced the commercial launch of Epioxa, an incision-free, oxygen- and light-activated corneal cross-linking therapy for keratoconus, now available directly and via specialty distributors.
By pairing this new therapy with expanded patient awareness, financial assistance, and access programs, Glaukos is aiming to tackle the long-standing underdiagnosis and undertreatment of this rare corneal disease.
We’ll now examine how Epioxa’s incision-free keratoconus...